PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 26, 2022European Heart Journal2,985 citationsOpen Access

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

ALAlexander R. LyonTLTeresa López‐FernándezLCLiam S. Couch

Key Points

  • Cardiac implantable electronic devices are critical in managing cardiovascular complications.
  • Patients aged 65-74 years and those with chronic myeloid leukaemia face unique cardiac risks.
  • Guidelines include advanced cardiac magnetic resonance techniques for better diagnosis and management of cardiac issues in cancer patients. Their implementation may improve patient outcomes during cancer treatment.

Abstract

65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic

Expert Takes7 quotes

1/7

“We're doing a lot of surveillance because one of the big advantages of cardio-oncology is we know when someone is about to get treated. You don't know in nature when someone's going to have an acute myocardial infarction or acute viral myocarditis, but we do know when they're coming into an oncology clinic to get an infusion of chemotherapy or tablets.”

Alexander R. Lyon, Cardiologist, Imperial College London and Royal Brompton HospitalImperial College Londonauto_pipelineSupportiveView source
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lyon et al. (2022) studied this question.

synapsesocial.com/papers/68fa84f9d15884e3fed6311chttps://doi.org/10.1093/eurheartj/ehac244
Ask AI
Helpful
Bookmark
Share
View Full Paper